Davis Bertans (Washington Wizards) with an and one vs the Sacramento Kings, 04/14/2021
Davis Bertans (Washington Wizards) with an and one vs the Sacramento Kings, 04/14/2021
Sentry's expanded platform capabilities help developers cut time to solve critical code-level issues by more easily surfacing context that matters.
MetroNet and the City of Bryan recently announced that MetroNet will be bringing its 100 percent fiber optic internet, TV and phone to businesses and residents within the City of Bryan. The City of Bryan is the first Texas market that MetroNet will partner with. MetroNet will fully fund the construction of their 100 percent fiber optic network in Bryan, providing residents and businesses with symmetrical, Gigabit speed internet service.
LogDNA announced a new browser logging capability, which makes it easier for developers to more efficiently debug web applications.
Winners recognized for excellence in security awareness training and simulated phishingTampa Bay, FL, May 06, 2021 (GLOBE NEWSWIRE) -- KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced the winners of its 2021 Sharky Awards. Organizations all over the world are making a concerted effort to improve their users’ ability to make better security decisions every day. The Sharky Awards recognize organizations and individuals for excellence in security awareness training. The winners for the 2021 Sharky Awards are as follows: Best Phishing Campaign: Arlington Community Federal Credit Union Best Landing Page: Neoway Solutions Best Security Awareness Plan: Q2Best User Story: ItConTop Product Advocate: Joel Scheller, CoServ Most Improved: Arlington Community Federal Credit UnionBest Phishing Template: Q2 “This past year has certainly been a challenge for cybersecurity professionals with the bad guys upping their game significantly,” said Stu Sjouwerman, CEO, KnowBe4. “That is why we are so proud to recognize those organizations and individuals who are embracing KnowBe4’s security awareness training and simulated phishing platform and implementing it successfully. We congratulate this year’s Sharky Award winners for their creative and unique approaches to tackling security awareness today.” All 2021 Sharky Award winners will receive a voucher to take the new H Layer Credentialing’s Security Awareness and Culture ProfessionalTM (SACP) certification exam. SACP professionals are knowledgeable of all facets of security awareness programs and maintain the highest professional standards. More information on the SACP is available at https://www.thehlayer.com/. To register to take the exam, visit https://portal.thehlayer.com/product/certification-exam. For more information on KnowBe4, visit www.knowbe4.com. About KnowBe4 KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 37,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as the last line of defense. CONTACT: Amanda Tarantino KnowBe4 7277484221 email@example.com
Nonuplets are extremely rare - and doctors had thought Halima Cissé was carrying seven babies.
Doma, a leading force for disruptive change in the real estate industry, expands its national footprint.
PEMBROKE, Bermuda, May 06, 2021 (GLOBE NEWSWIRE) -- James River Group Holdings, Ltd. (NASDAQ: JRVR) (the “Company”) announced today that it has priced the previously announced underwritten public offering of 5,650,000 of its common shares at a price to the public of $31.00 per share or an aggregate of $175,150,000. The Company expects to use the net proceeds from the offering for general corporate purposes. The offering is expected to close on May 10, 2021, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 847,500 additional common shares at the public offering price, less the underwriting discounts and commissions. Barclays and Keefe, Bruyette & Woods, a Stifel Company, are acting as joint lead book-running managers for the offering and as representatives of the underwriters for the offering. BMO Capital Markets, KeyBanc Capital Markets and Truist Securities are also acting as book-running managers for the offering. B. Riley Securities, Compass Point, Dowling & Partners Securities, LLC and JMP Securities are acting as co-managers for the offering. The offering is being made only by means of the applicable prospectus supplement and accompanying prospectus. A preliminary prospectus supplement relating to and describing the terms of the offering were filed with the Securities and Exchange Commission (“SEC”) and are available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of these documents, when available, may also be obtained by contacting Barclays Capital Inc., by calling (888) 603-5847 or by email at Barclaysprospectus@broadridge.com, or Keefe, Bruyette & Woods, Inc., by calling (212) 887-7777 or by email at firstname.lastname@example.org. The common shares are being offered by the Company pursuant to an effective shelf registration statement filed by the Company with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. In some cases, such forward-looking statements may be identified by terms such as believe, expect, seek, may, will, intend, project, anticipate, plan, estimate or similar words. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Although it is not possible to identify all of these risks and factors, they include, among others, the satisfaction of closing conditions, the possibility that incurred losses may be greater than the Company’s loss and loss adjustment expenses reserves, inaccurate estimates and judgements exposing the Company to greater risk than intended, downgrades in the financial strength rating of our regulated insurance subsidiaries, the potential loss of key members of our management team and adverse economic factors impacting the number of policies sold or an increase in the frequency or severity of claims. These forward-looking statements speak only as of the date of this release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the “Risk Factors” sections in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and Quarterly Report on Form 10-Q for the three months ended March 31, 2021, as well as subsequent filings made by the Company with the SEC. About the CompanyJames River Group Holdings, Ltd. is a Bermuda-based insurance holding company which owns and operates a group of specialty insurance and reinsurance companies. The Company operates in three specialty property-casualty insurance and reinsurance segments: Excess and Surplus Lines, Specialty Admitted Insurance and Casualty Reinsurance. The Company is headquartered in Pembroke, Bermuda. CONTACT: Contact: James River Group Holdings, Ltd. Sarah Casey Doran Chief Financial Officer InvestorRelations@jrgh.net (441) 278-4580
This has been an unprecedented year for nurses as they have faced the challenges of a global pandemic. Many have worked long hours, seen changes in their job duties and have experienced anxiety about their own health and safety and that of their families. As part of recognizing National Nurses Week, May 6-12, University of Phoenix commissioned The Harris Poll to survey 300 nurses across the nation to better understand their perception of the nursing profession since the start of the pandemic.
David Swensen, who spent more than three decades managing one of the world's best performing college endowments as Yale University's chief investment officer, has died of cancer, the university said. Swensen pioneered investments in hedge funds, private equity and real estate, creating a model, known as the "Yale Model," that many endowments have sought to emulate over the years. Swensen, who earned a Ph.D. in economics from Yale, returned to his alma mater in 1985 after working on Wall Street for several years.
A Central Kentucky man died Wednesday after being swept underwater while kayaking with his fiancee, according to Scott County Coroner John Goble.
Halima Cissé, 25, gave birth to nonuplets at a clinic in Morocco in an "extremely rare" case.
The supermarket chain said she will take the role of general merchandise and clothing commercial director in June.
David Harbour previously told PEOPLE that the forthcoming season will "see a lot of your favorite characters doing the thing that you love them for"
Here's why WELL Health stock can outpace the TSX in 2021 and beyond. The post Why This Digital Health Stock on the TSX Remains a Solid Long-Term Pick! appeared first on The Motley Fool Canada.
Republican Ron DeSantis signed into law legislation that significantly restricts voter access to mail-in ballots and drop boxes.
Scotiabank will announce its second quarter results on Tuesday June 1, 2021.
ORLANDO, Fla. — The Orlando Magic are offering the coronavirus vaccine to as many as 2,300 Central Florida residents next week, becoming the latest NBA team to host such an event. The Magic partnered with AdventHealth and city officials to arrange the May 13 event at Amway Center, the team’s home arena. The Moderna vaccine will be available, free of charge, to anyone 18 or older. State officials say more than 2.2 million Florida residents have tested positive for COVID-19, including about 135,000 from Orange County — which includes Orlando. City officials note that having the event at Amway Center could encourage vulnerable citizens to get the vaccine. “Having the vaccine in this historically Black community will surely save the lives of many,” Orlando District 5 Commissioner Regina Hill said. Magic coach Steve Clifford recently missed several games after testing positive for the coronavirus, though said he felt no symptoms at any time because he had received the vaccine. “Because I’ve been vaccinated, I really had no discomfort,” Clifford said. “I didn’t have any symptoms at all, so it was very uneventful, thankfully. And from what I’ve been told, the biggest part is I’ve been vaccinated so my body was ready.” Those who register for the vaccine event will be scheduled to receive their second vaccine on June 10, also at Amway Center. Several other NBA teams have offered the vaccine to fans or used their arenas to host vaccination events in concert with local government and health officials. ___ More AP NBA: https://apnews.com/hub/NBA and https://twitter.com/AP_Sports The Associated Press
EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the first quarter ended March 31, 2021 and reviewed business highlights. “The momentum we generated in the first quarter -- with the launch of two novel programs in a new therapeutic category of infectious disease, the execution of multiple collaborations with notable government, private and nonprofit institutions, and the continued advancement of our oncology clinical programs – reflects the significant interest in our innovative, antigen-directed clinical-stage immunotherapies,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. “We expect this activity level to extend into the rest of the year. We are continuing patient dosing and follow-up in our GRANITE program and will be submitting these data for presentation at ESMO. Additionally, we expect to have data from our CORAL COVID-19 program available later this year. Finally, we will be initiating multiple clinical studies in oncology and infectious disease in 2021.” Key AccomplishmentsNeoantigen Oncology Programs Continued enrolling and treating patients with advanced cancer in single-arm Phase 2 expansion cohorts with GRANITE, an individualized neoantigen immunotherapy, as a late-line therapy for metastatic microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal (GEA) cancer and non-small cell lung cancer (NSCLC)Continued enrolling and treating patients in single-arm Phase 2 expansion cohorts with version 1 (v1) of SLATE, a shared neoantigen immunotherapy Infectious Disease Programs Announced the launch of our CORAL COVID-19 program to develop a second-generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both more durable protection and broader immunity against Spike and additional non-Spike antigens, compared with first-generation “Spike-only” vaccines which can be impacted by emerging variants of concern in Spike sequenceBegan dosing volunteers in a Phase 1 CORAL clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted through the Infectious Diseases Clinical Research Consortium (IDCRC)Established a collaboration with Gilead Sciences (Gilead) to develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection, and received $60 million in proceeds as a part of the collaboration Anticipated Remaining 2021 Milestones Submit an abstract to the European Society for Medical Oncology (ESMO) conference in September 2021 to present GRANITE data, including longer-term follow-up of late-stage, advanced disease patients who remain in the Phase 1 study, in addition to preliminary data from the Phase 2 cohorts in the same disease contextAdvance the SLATE program by initiating a study with the version two (v2) cassette optimized for KRAS neoantigens for patients with NSCLC, and sharing data from SLATE v1 cohorts in the third quarter of 2021Initiate a company-sponsored COVID-19 clinical study in the third quarter of 2021, evaluating a novel vaccine containing Spike and other SARS-CoV-2 epitopes as a boost after first generation vaccinationShare NIAID-IDCRC Phase 1 COVID-19 vaccine data in the third quarter of 2021Share initial COVID-19 vaccine boost data in the fourth quarter of 2021Initiate two randomized Phase 2 trials of GRANITE in earlier-stage cancer patients in the second half of 2021Launch a new SLATE program, centered on an undisclosed shared neoantigen, at the end of 2021 First Quarter 2021 Financial ResultsFor the three months ended March 31, 2021, Gritstone reported net income of $7.9 million, compared to a net loss of $26.2 million for the three months ended March 31, 2020. The increase in net income was due to an increase in license fee revenue. Collaboration and license revenue was $39.7 million for the three months ended March 31, 2021, compared to $1.3 million for the three months ended March 31, 2020. The increase was due to the license revenue associated with the Gilead Collaboration Agreement entered into in January 2021. Total research and development expenses were $24.9 million for the three months ended March 31, 2021, compared to $22.5 million for the three months ended March 31, 2020. The increase was primarily attributable to an increase in milestone and license payments, as well as personnel-related expenses. General and administrative expenses were $6.9 million for the three months ended March 31, 2021, compared to $5.5 million for the three months ended March 31, 2020. The increase was primarily attributable to an increase in outside professional services. Cash, cash equivalents, marketable securities and restricted cash were $199.0 million as of March 31, 2021 compared to $172.1 million as of December 31, 2020. About Gritstone Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com. Gritstone Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in the company’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on May 6, 2021 and any current and periodic reports filed with the Securities and Exchange Commission. ContactsMedia:Dan Budwick1AB(973) email@example.com Investors:Alexandra Santos Wheelhouse Life Science Advisors(510) firstname.lastname@example.org Gritstone bio, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In thousands, except share and per share data) Three Months Ended March 31, 2021 2020 Revenue: Collaboration and license revenues$39,693 $1,262 Total revenue 39,693 1,262 Operating expenses: Research and development 24,856 22,468 General and administrative 6,941 5,465 Total operating expenses 31,797 27,933 Income (loss) from operations 7,896- (26,671)Interest and other income, net$27 $465 Net income (loss)$7,923 $(26,206)Net income (loss) per common share, basic$0.10 $(0.71)Shares used to compute for net income (loss) per common share, basic and diluted 75,987,372 36,798,562 Net income (loss) per common share, diluted$0.10 $(0.71)Shares used to compute for net income (loss) per common share, basic and diluted 77,464,356 36,798,562 Gritstone bio, Inc.Condensed Consolidated Balance Sheets(Unaudited)(In thousands) March 31,2021 December 31,2020 Assets Current assets: Cash and cash equivalents$108,505 $170,056 Marketable securities 89,501 1,002 Prepaid expenses and other current assets 4,507 4,332 Total current assets 202,513 175,390 Property and equipment, net 21,693 22,105 Operating lease right-of-use assets 19,997 21,344 Deposits and other long-term assets 2,736 2,728 Total assets$246,939 $221,567 Liabilities and stockholders' equity Current liabilities: Accounts payable$6,368 $9,578 Accrued compensation 3,821 6,331 Accrued liabilities 571 677 Accrued research and development 1,558 1,053 Lease liabilities, current portion 6,075 5,874 Deferred revenue, current portion 3,386 3,475 Total current liabilities 21,779 26,988 Other non-current liabilities 395 395 Lease liabilities, net of current portion 17,619 19,225 Deferred revenue, net of current portion 7,795 8,220 Total liabilities 47,588 54,828 Commitments and contingencies Stockholders' equity: Convertible preferred stock - - Common stock 18 18 Additional paid-in capital 517,715 493,023 Accumulated other comprehensive loss (3) - Accumulated deficit (318,379) (326,302)Total stockholders' equity 199,351 166,739 Total liabilities and stockholders' equity$246,939 $221,567
T-Mobile (NASDAQ: TMUS) continues its mission to fuel 5G innovation, with applications now open for the Fall 2021 T-Mobile Accelerator Wellness Technology Program. T-Mobile Accelerator is actively searching for startups developing the next big thing in 5G technologies that promote healthy living and improve quality of life, from personal fitness wearables that enhance sports performance to telehealth services, digital wellness applications, biomedical monitoring and more. The application window closes June 25, 2021 and the fall program begins August 9, 2021.
All-in-one office suite builds on renowned Microsoft Office compatibility, adds workflow enhancements and new in-application feedback. Introducing WordPerfect Office 2021 Delivering complete office suite power, WordPerfect Office 2021 advances its legendary document creation with enhanced file format support, a streamlined workflow and more. OTTAWA, May 06, 2021 (GLOBE NEWSWIRE) -- Delivering complete office suite power, WordPerfect Office 2021 advances its legendary document creation with enhanced file format support, a streamlined workflow and more, enabling users to be more productive and access essential tools and functions quicker and easier than before. “Building on the features our customers depend on, WordPerfect Office 2021 solidifies its longstanding reputation as an essential office suite for creating impressive documents. The latest version is designed to support our users’ everyday work needs with updates to many of our most-used tools, including file compatibility, PDF publishing and access to vital document stats, that make it simpler to get work done,” said John Falsetto, Senior Director of Products, Graphics and Productivity at Corel. “Over the years, our passionate customer base has been key in shaping our product enhancements. To make this direct communication with the WordPerfect team even better, we’ve now added the new ability to send us feedback directly within the products themselves. We encourage our users to reach out, submit suggestions and play a direct role in helping shape the future of this legendary suite.” A popular choice with users in legal, government and business, WordPerfect® Office 2021 is ideal for creating impressive documents, presentations and spreadsheets. The suite comes complete with PDF functionality; legal-specific features and tools; a built-in Oxford Concise Dictionary; a powerful Macro Manager; Reveal Codes for full document formatting control; and support for over 60 file types. Network deployment for corporate accounts makes WordPerfect Office 2021 ideal for any office environment. Work more efficiently with user-requested features Responding to top customer requests, WordPerfect® now makes it simple to access vital document statistics, such as word count, character, line count and more with just a click. Quickly pinpoint data in sheets and across documents in Quattro Pro thanks to a newly redesigned search-and-replace workflow and the ability to reuse recently used search criteria. Clear active search criteria in WordPerfect in a click, making it easier and faster to perform multiple find-and-replace actions. Plus, to ensure that our customers’ top requests help shape future development, users can give feedback, vote and make suggestions about WordPerfect, Quattro Pro and Presentations from directly within the application. Enjoy improved file compatibility, helpful resources and enhanced performance Experience enhanced compatibility with the latest Microsoft Office file formats, along with new JBIG file support that makes importing PDFs made up of multiple scanned images smoother than before. Get access to phrases, phonetic spellings, scientific and specialist words in WordPerfect Office 2021 using the built-in Oxford Concise Dictionary. Enterprise customers can now take advantage of improved performance and file stability when opening or saving files directly to a server. WordPerfect Office Standard 2021 includes: WordPerfect® word processorQuattro Pro™ spreadsheet applicationPresentations™ slideshow creatorWordPerfect® Lightning™ digital notebookeBook PublisherNEW! Oxford Concise DictionaryAfterShot™ 3 photo-editing and management900 TrueType fonts; over 10,000 clipart images; over 300 templates; over 175 digital photos; the WordPerfect Address Book; the Presentations Graphics bitmap editor and drawing application; the WordPerfect XML Project Designer; and much more. Pricing and Availability WordPerfect Office 2021 is available in English and French. Suggested retail pricing (SRP) for WordPerfect Office Standard 2021 is $249.99 USD. SRP for WordPerfect Office Home & Student 2021 is $99.99 USD. SRP for WordPerfect Office Professional 2021 is $399.99 USD. To learn more about WordPerfect Office licensing options for business, government and education, including volume licensing and network deployment, visit www.wordperfect.com/licensing/. For more information and to download a free trial, please visit www.wordperfect.com. About Corel Corel products enable millions of connected knowledge workers around the world to do great work faster. Offering some of the industry's best-known software brands, we give individuals and teams the power to create, collaborate and deliver impressive results. Our success is driven by an unwavering commitment to deliver a broad portfolio of innovative applications – including CorelDRAW®, MindManager®, Parallels® and WinZip® – to inspire users and help them achieve their goals. To learn more about Corel, please visit www.corel.com. ©2021 Corel Corporation. All rights reserved. Corel, the Corel logo, the Corel Balloon logo, WordPerfect, AfterShot, CorelDRAW, Lightning, MindManager, Presentations, Quattro Pro, and WinZip are trademarks or registered trademarks of Corel Corporation in Canada, the U.S., and/or elsewhere. Parallels is a trademark or registered trademark of Parallels International GmbH in Canada, the U.S., and elsewhere. All other company, product and service names, logos, brands, and any registered or unregistered trademarks mentioned are used for identification purposes only and remain the exclusive property of their respective owners. Use of any brands, names, logos, or any other information, imagery, or materials pertaining to a third party does not imply endorsement. We disclaim any proprietary interest in such third-party information, imagery, materials, marks, and names of others. For all notices and information about patents, please visit www.corel.com/patent. Media Contact: Ashley RuessPublic Relations Managerashley.email@example.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/25f0f9fa-37f3-43df-bde1-4f2b665374d3